Nuvo Pharmaceuticals Stock Price, News & Analysis (TSE:NRI)

C$3.89 -0.05 (-1.27 %)
(As of 01/17/2018 07:32 AM ET)
Previous CloseC$3.94
Today's RangeC$3.89 - C$3.96
52-Week RangeC$3.50 - C$6.43
Volume77,954 shs
Average Volume16,812 shs
Market CapitalizationC$44.93 million
P/E Ratio12.97
Dividend YieldN/A
Beta-0.85

About Nuvo Pharmaceuticals (TSE:NRI)

Nuvo Pharmaceuticals Inc., formerly Nuvo Research Inc., is a Canada-based healthcare company. The Company offers a range of commercial products, including Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine (HLT) patch. The Company's Pennsaid 2% is a non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium. Its Pennsaid 2% is indicated for treating the pain of osteoarthritis (OA) of the knee and also acute strains and sprains. The Company's Pennsaid is a topical pain product, which is used to treat the signs and symptoms of OA of the knee. The Pennsaid combines the transdermal carrier with diclofenac sodium, which is a NSAID and delivers the active drug through the skin at the site of pain. Its HLT Patch is a topical patch that combines lidocaine, tetracaine and heat, using Controlled Heat-Assisted Drug Delivery (CHADD) technology. HLT Patch provides local analgesia prior to painful needle procedures, such as dialysis, blood draws and pediatric needles.

Receive NRI News and Ratings via Email

Sign-up to receive the latest news and ratings for NRI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealthcare
SymbolTSE:NRI
CUSIPN/A
Phone+1-905-6736980

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio12.9666666666667
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC$0.30
Net IncomeN/A
Net Margins-7.65%
Return on Equity-3.60%
Return on Assets-3.35%

Miscellaneous

EmployeesN/A
Outstanding Shares11,551,000

Nuvo Pharmaceuticals (TSE:NRI) Frequently Asked Questions

What is Nuvo Pharmaceuticals' stock symbol?

Nuvo Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NRI."

How were Nuvo Pharmaceuticals' earnings last quarter?

Nuvo Pharmaceuticals Inc (TSE:NRI) announced its quarterly earnings data on Wednesday, November, 1st. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.07 by $0.09. Nuvo Pharmaceuticals had a negative net margin of 7.65% and a negative return on equity of 3.60%. View Nuvo Pharmaceuticals' Earnings History.

When will Nuvo Pharmaceuticals make its next earnings announcement?

Nuvo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Nuvo Pharmaceuticals.

Who are some of Nuvo Pharmaceuticals' key competitors?

Who are Nuvo Pharmaceuticals' key executives?

Nuvo Pharmaceuticals' management team includes the folowing people:

  • John C. London, Executive Chairman of the Board
  • Jesse Francis Ledger, President, Chief Executive Officer
  • Mary-Jane Eleanor Burkett, Chief Financial Officer, Vice President
  • Henrich R. K. Guntermann M.D., President of Europe and Immunology Group, Director
  • Katina Loucaides, Vice President, General Counsel, Secretary
  • David A. Copeland, Lead Independent Director
  • Daniel H. Chicoine, Director
  • Samira Sakhia CPA, Director
  • Anthony E. Dobranowski, Independent Director
  • Jacques Messier, Independent Director

How do I buy Nuvo Pharmaceuticals stock?

Shares of Nuvo Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Nuvo Pharmaceuticals' stock price today?

One share of Nuvo Pharmaceuticals stock can currently be purchased for approximately C$3.89.

How big of a company is Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals has a market capitalization of C$44.93 million.

How can I contact Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals' mailing address is 7560 Airport Rd Unit 10, MISSISSAUGA, ON L4T 4H4, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-6736980.


MarketBeat Community Rating for Nuvo Pharmaceuticals (NRI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  62
MarketBeat's community ratings are surveys of what our community members think about Nuvo Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nuvo Pharmaceuticals (TSE:NRI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.002.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Nuvo Pharmaceuticals (TSE:NRI) Consensus Price Target History

Price Target History for Nuvo Pharmaceuticals (TSE:NRI)

Nuvo Pharmaceuticals (TSE:NRI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/3/2017Bloom BurtonDowngradeBuy -> AccumulateView Rating Details
3/23/2016LaurentianSet Price TargetBuyC$8.00View Rating Details
3/23/2016Laurentian Bank of CanadaInitiated CoverageC$8.00View Rating Details
3/1/2016M PartnersReiterated RatingBuyView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Nuvo Pharmaceuticals (TSE:NRI) Earnings History and Estimates Chart

Earnings by Quarter for Nuvo Pharmaceuticals (TSE:NRI)

Nuvo Pharmaceuticals (TSE NRI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/1/2017Q3 2017C$0.07C($0.02)ViewN/AView Earnings Details
8/9/2017Q2 2017C($0.07)C($0.02)ViewN/AView Earnings Details
5/10/2017Q1 2017C$0.17C$0.19ViewN/AView Earnings Details
3/1/2017Q4 2016C$0.24C$0.12ViewN/AView Earnings Details
11/10/2016Q3 2016C$0.22C$0.10ViewN/AView Earnings Details
8/10/2016Q2 2016C$0.21ViewN/AView Earnings Details
5/11/2016Q1 2016C$0.15ViewN/AView Earnings Details
2/17/2016Q4 2015C($0.38)C$0.03ViewN/AView Earnings Details
11/10/2015Q3 2015C($0.40)C($0.11)ViewN/AView Earnings Details
8/5/2015Q2 2015C($0.10)C($0.55)ViewN/AView Earnings Details
5/12/2015Q1 2015C($0.39)C($0.03)ViewN/AView Earnings Details
2/19/2015Q4 2014C($0.30)C($0.56)ViewN/AView Earnings Details
11/10/2014Q3 2014C($0.28)C($0.25)ViewN/AView Earnings Details
7/30/2014C($0.25)C($0.23)C$3.30 millionC$3.86 millionViewN/AView Earnings Details
4/30/2014Q1 2014C($0.31)ViewN/AView Earnings Details
2/20/2014Q4 2013C($0.38)C($0.22)ViewN/AView Earnings Details
10/30/2013Q3 2013C$0.36C$0.39ViewN/AView Earnings Details
7/31/2013Q2 2013C($0.16)C($0.25)ViewN/AView Earnings Details
5/1/2013Q1 2013C($24.68)ViewN/AView Earnings Details
10/31/2012Q3 2012C$0.65ViewN/AView Earnings Details
8/1/2012Q2 2012C$0.39ViewN/AView Earnings Details
5/2/2012Q1 2012C($0.26)ViewN/AView Earnings Details
2/29/2012Q4 2011C($0.32)ViewN/AView Earnings Details
11/2/2011Q3 2011C($0.19)ViewN/AView Earnings Details
8/10/2011Q2 2011C($0.19)ViewN/AView Earnings Details
5/26/2011Q1 2011C($0.65)ViewN/AView Earnings Details
2/24/2011Q4 2010C($0.26)ViewN/AView Earnings Details
10/27/2010Q3 2010C($0.32)ViewN/AView Earnings Details
7/29/2010Q2 2010C($0.45)ViewN/AView Earnings Details
4/29/2010Q1 2010C($0.52)ViewN/AView Earnings Details
2/19/2010Q4 2009C$3.90ViewN/AView Earnings Details
10/28/2009Q3 2009C($0.45)ViewN/AView Earnings Details
8/7/2009Q2 2009C($0.32)ViewN/AView Earnings Details
4/30/2009Q1 2009C($0.58)ViewN/AView Earnings Details
10/30/2008Q3 2008C($0.65)ViewN/AView Earnings Details
7/31/2008Q2 2008C($0.58)ViewN/AView Earnings Details
5/1/2008Q1 2008C($0.52)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Nuvo Pharmaceuticals (TSE:NRI) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nuvo Pharmaceuticals (TSE:NRI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Nuvo Pharmaceuticals (TSE NRI) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Nuvo Pharmaceuticals (TSE:NRI)

Nuvo Pharmaceuticals (TSE NRI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2016Samira SakhiaDirectorBuy10,000C$5.20C$52,000.00
11/14/2014Anthony Edward DobranowskiDirectorSell3,846C$6.97C$26,803.54
(Data available from 1/1/2013 forward)

Headlines

Nuvo Pharmaceuticals (TSE NRI) News Headlines

Source:
DateHeadline
Toronto Exchanges Stock Review Valeant Pharmaceuticals International Knight Therapeutics and Nuvo PharmaceuticalsToronto Exchanges Stock Review Valeant Pharmaceuticals International Knight Therapeutics and Nuvo Pharmaceuticals
finance.yahoo.com - December 18 at 9:26 AM
Nuvo Pharmaceuticals™ Enters into Pennsaid® 2% License Agreement with Gebro Pharma AG for Switzerland and LiechtensteinNuvo Pharmaceuticals™ Enters into Pennsaid® 2% License Agreement with Gebro Pharma AG for Switzerland and Liechtenstein
www.prnewswire.com - December 14 at 7:52 AM
Nuvo Pharmaceuticals™ Announces Normal Course Issuer BidNuvo Pharmaceuticals™ Announces Normal Course Issuer Bid
finance.yahoo.com - December 9 at 9:16 AM
OTC Markets Group Welcomes Nuvo Pharmaceuticals to OTCQX - PR Newswire (press release)OTC Markets Group Welcomes Nuvo Pharmaceuticals to OTCQX - PR Newswire (press release)
www.prnewswire.com - November 28 at 10:22 AM
Does Nuvo Pharmaceuticals Inc’s (TSX:NRI) -66.8% EPS Decline Reflect A Long-Term Trend?Does Nuvo Pharmaceuticals Inc’s (TSX:NRI) -66.8% EPS Decline Reflect A Long-Term Trend?
finance.yahoo.com - November 21 at 8:46 AM
Canadian Healthcare Stocks under Review, Valeant Pharma International, Knight Therapeutics, Acerus Pharma, and Nuvo PharmaCanadian Healthcare Stocks under Review, Valeant Pharma International, Knight Therapeutics, Acerus Pharma, and Nuvo Pharma
finance.yahoo.com - November 9 at 9:27 AM
Today’s Research Reports on Cardiome Pharma, IntelliPharmaCeutics International, Nuvo Pharmaceuticals and Oncolytics Biotech Inc.Today’s Research Reports on Cardiome Pharma, IntelliPharmaCeutics International, Nuvo Pharmaceuticals and Oncolytics Biotech Inc.
finance.yahoo.com - November 9 at 9:27 AM
Nuvo Pharmaceuticals Inc (NRI) Lowered to Accumulate at Bloom BurtonNuvo Pharmaceuticals Inc (NRI) Lowered to Accumulate at Bloom Burton
www.americanbankingnews.com - November 4 at 12:53 PM
Edited Transcript of NRI.TO earnings conference call or presentation 2-Nov-17 12:30pm GMTEdited Transcript of NRI.TO earnings conference call or presentation 2-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 8:09 AM
Should You Buy Nuvo Pharmaceuticals Inc (TSX:NRI) At $4.09?Should You Buy Nuvo Pharmaceuticals Inc (TSX:NRI) At $4.09?
finance.yahoo.com - November 4 at 8:09 AM
Nuvo Pharmaceuticals, Inc. :NRI-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Nuvo Pharmaceuticals, Inc. :NRI-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 8:09 AM
Nuvo Pharmaceuticals, Inc. :NRI-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017Nuvo Pharmaceuticals, Inc. :NRI-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017
finance.yahoo.com - August 15 at 4:24 PM
Edited Transcript of NRI.TO earnings conference call or presentation 10-Aug-17 12:00pm GMTEdited Transcript of NRI.TO earnings conference call or presentation 10-Aug-17 12:00pm GMT
finance.yahoo.com - August 11 at 6:59 AM
Nuvo Pharmaceuticals, Inc. :NRI-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017Nuvo Pharmaceuticals, Inc. :NRI-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 4 at 6:27 AM
BRIEF-Nuvo Pharmaceuticals announces Q1 EPS C$0.19BRIEF-Nuvo Pharmaceuticals announces Q1 EPS C$0.19
www.reuters.com - May 12 at 12:22 AM
Nuvo Pharmaceuticals Is Now Oversold (NRI)Nuvo Pharmaceuticals Is Now Oversold (NRI)
www.thestreet.com - May 8 at 6:21 PM
Research Reports Initiated on Healthcare Stocks Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and Avivagen - Baystreet.caResearch Reports Initiated on Healthcare Stocks Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and Avivagen - Baystreet.ca
www.baystreet.ca - December 2 at 6:33 PM
Nuvo To Split Into Two, BSPM Regains Compliance, PFE Gets FDA Nod - NasdaqNuvo To Split Into Two, BSPM Regains Compliance, PFE Gets FDA Nod - Nasdaq
www.nasdaq.com - February 26 at 1:31 PM
Nuvo Research® Inc. Obtains Final Court Order Approving Reorganization into Two Publicly-Traded Companies - PR Newswire (press release)Nuvo Research® Inc. Obtains Final Court Order Approving Reorganization into Two Publicly-Traded Companies - PR Newswire (press release)
www.prnewswire.com - February 26 at 1:31 PM
Nuvo Research® Provides Estimated Revenue for the 2015 Fourth Quarter and Year End - PR Newswire (press release)Nuvo Research® Provides Estimated Revenue for the 2015 Fourth Quarter and Year End - PR Newswire (press release)
www.prnewswire.com - January 21 at 1:26 PM

SEC Filings

Nuvo Pharmaceuticals (TSE:NRI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Nuvo Pharmaceuticals (TSE NRI) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.